Insight: Demographic Differences and Associations with One-Year Outcome in Schizophrenia and Schizoaffective Disorder

2010 ◽  
Vol 4 (3) ◽  
pp. 169-175 ◽  
Author(s):  
Benjamin Wiffen ◽  
Jonathan Rabinowitz ◽  
W. Fleischhacker ◽  
Anthony David
Keyword(s):  
Schizoaffective Disorder ◽  
Demographic Differences ◽  
One Year

scholarly journals The case of inorganic hypersomnia treated with light therapy in the course of schizoaffective disorder

2016 ◽  
Vol 17 (1) ◽  
pp. 17-18
Author(s):  
Jolanta Masiak ◽  
Elżbieta Masiak ◽  
Katarzyna Ziniuk
Keyword(s):  
Mental Disorders ◽  
Schizoaffective Disorder ◽  
Excessive Daytime Sleepiness ◽  
Light Therapy ◽  
Mood Stabilizers ◽  
Definite Evidence ◽  
Her Family ◽  
Icd 10 ◽  
One Year

AbstractAccording to ICD 10, nonorganic hypersomnia is defined as “a condition of either excessive daytime sleepiness and sleep attacks (not accounted for by an inadequate amount of sleep) or prolonged transition to the fully aroused state upon awakening. When no definite evidence of organic etiology can be found, this condition is usually associated with mental disorders”. The severe hypersomnia in the course of schizoaffective disorder is rather a rare phenomenon. The paper presents the case of 41-year-old female patient with severe hypersomnia during the course of the schizoaffective disorder. The course of hypersomnia was severe. The patient slept constantly day and night and was awoken by her family for about three-hour period of time. The duration of hypersomnia was about one year until the onset of treatment. The patient was successfully treated with light therapy that caused gradual resolution of the symptoms of hypersomnia. The patient is also treated as prior to the onset of hypersomnia with antipsychotics and the mood stabilizers for schizoaffective disorder. Since that time there were six-year-period of follow up when the patient was free of any symptoms of hypersomnia.

Remission in schizophrenia: one-year Italian prospective study of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder

2009 ◽  
Vol 24 (7) ◽  
pp. 574-583 ◽  
Author(s):  
Alessandro Rossi ◽  
Anna Bagalà ◽  
Vincenzo Del Curatolo ◽  
Francesco Scapati ◽  
Micaela Maria Bernareggi ◽  
...  
Keyword(s):  
Prospective Study ◽  
Schizoaffective Disorder ◽  
One Year ◽  
Long Acting

Treatment with intramuscular paliperidone palmitate in schizoaffective disorder

2016 ◽  
Vol 33 (S1) ◽  
pp. S581-S581
Author(s):  
L. Maroto Martin ◽  
P. Hervías Higueras
Keyword(s):  
Schizoaffective Disorder ◽  
Complex Disease ◽  
Psychotic Disorders ◽  
Paliperidone Palmitate ◽  
Valuable Treatment ◽  
History Of ◽  
Competing Interest ◽  
One Year ◽  
Long Acting ◽  
Monthly Dose

IntroductionInjectable formulations of long acting antipsychotic are a valuable treatment option for patients with psychotic disorders. Schizoaffective Disorder (SAD) is a complex disease; the optimal treatment is not well established yet.ObjectiveAnswer the question about the effectiveness offered by intramuscular Paliperidone Palmitate in SAD versus other injectable antipsychotics. Keywords: schizoaffective disorder; paliperidone palmitate injection.MethodsA case report of a 35-year-old male diagnosed with Schizoaffective Disorder six years ago and with personal history of multiple manic decompensation after treatment discontinuation. Throughout his life he has been treated with intramuscular Risperidone 87.5 mg (50 + 37.5) every 14 days, Olanzapine flas 20 mg/day, Risperidone flas 3 mg, Amisulpride 600 mg/day, Valproic acid 1500 mg/day Clonazepam 2 mg/day and Lormetazepam 1 mg. In the last admission one year ago, he started treatment with intramuscular paliperidone palmitate up to 200 mg a month. Currently he receives a monthly dose of 100 mg and concomitant lithium 800 mg/day.DiscussionThe use of intramuscular paliperidone palmitate in SAD and its effectiveness against other injectable antipsychotic is discussed.ConclusionsThe use of intramuscular paliperidone palmitate appears to constitute an employment opportunity in the treatment of intramuscular maintenance in SAD. It could be effective in stabilizing episodes of acute exacerbation and remissions of psychotic, manic and depressive symptoms.Disclosure of interestThe authors have not supplied their declaration of competing interest.

Schizoaffective Disorder in a Fragile-X Carrier

1999 ◽  
Vol 33 (3) ◽  
pp. 436-440 ◽  
Author(s):  
Yousef Al-Semaan ◽  
Ashok K. Malla ◽  
Andrea Lazosky
Keyword(s):  
Complete Remission ◽  
Executive Functions ◽  
Social Functioning ◽  
Schizoaffective Disorder ◽  
Clinical Picture ◽  
Initial Treatment ◽  
Antipsychotic Drugs ◽  
Fragile X ◽  
Female Carrier ◽  
One Year

Objective: Here we report the case of a schizoaffective psychosis in a female carrier of fragile-X (CGG sequence > 200). Clinical picture: The patient presented with symptoms of psychosis (hallucinations, delusions and disorganised thinking) and mania, preceded by decline in intellectual and social functioning. Treatment and outcome: Initial treatment with antipsychotic drugs alone or in combination with sodium valproate was only partially effective, but the addition of lithium resulted in a complete remission. Conclusions: One year later the patient presented predominantly with deficit symptoms and profound deficits in memory and executive functions. It is likely that the intellectual deterioration around the time of puberty associated with fragile-X increased her vulnerability to a schizoaffective disorder and eventually to poor functioning.

Olanzapine versus haloperidol in the treatment of schizoaffective disorder

1999 ◽  
Vol 174 (1) ◽  
pp. 15-22 ◽  
Author(s):  
Pierre V. Tran ◽  
Gary D. Tollefson ◽  
Todd M. Sanger ◽  
Yili Lu ◽  
Paul H. Berg ◽  
...  
Keyword(s):  
Weight Gain ◽  
Adverse Events ◽  
Maintenance Therapy ◽  
Schizoaffective Disorder ◽  
International Study ◽  
Double Blind ◽  
Additional Improvement ◽  
One Year ◽  
Term Maintenance

BackgroundThe effectiveness of antipsychotic monotherapy in schizoaffective disorder is limited, and further constrained by safety concerns.AimsWe aimed to compare the efficacy, tolerability and safety profile of the new pharmaceutical, olanzapine, with haloperidol.MethodData were assessed from 300 DSM – III – R schizoaffective subjects from a larger double-blind prospective international study. Subjects were randomly allocated to six weeks of olanzapine (5–20 mg) or haloperidol (5–20 mg) treatment; responders were followed for up to one year of double-blind, long-term maintenance therapy.ResultsOlanzapine-treated patients achieved a statistically significant greater improvement than haloperidol-treated patients on overall measures of efficacy, including clinical response. Significantly fewer olanzapine patients left the study early, and fewer adverse events were observed among those receiving olanzapine. During maintenance, olanzapine-treated patients continued to experience additional improvement, with fewer EPS but more weight gain than those on haloperidol.ConclusionsOlanzapine demonstrated substantial advantages over the conventional antipsychotic haloperidol in the management of schizoaffective disorder.

scholarly journals Altruistic Surrogacy – Ethical Issues and Demographic Differences in Public Opinion

2017 ◽  
Vol 44 (2) ◽  
pp. 44-48
Author(s):  
R. Krastev ◽  
V. Mitev
Keyword(s):  
Marital Status ◽  
Online Survey ◽  
Ethical Issues ◽  
University Education ◽  
Demographic Differences ◽  
Same Sex Couples ◽  
Poor Women ◽  
One Year ◽  
Medical University ◽  
Bulgarian People

AbstractThis is the first study of the attitude of Bulgarian people towards the allowing of altruistic surrogacy which is prohibited in Bulgaria. This study used an online survey which was active during one year (July 2010-June 2011) and which was answered by 951 respondents between 18-65 years of age. The majority of them (87%) are young people between 18-43 years. The respondents are men and women with secondary, university and medical university education from the capital and the countryside. They have different marital status. The data were treated with statistical package SPSS 16. The link between the demographic characteristics (gender, age, education, marital status and place of residence) and the answers of the respondents was identified. The majority of the respondents (73%) think that the altruistic surrogacy must be allowed in Bulgaria and the main supporters are the women and the residents in the countryside – married or living with partner. Only 38% of the respondents mostly divorced middle aged persons accept the access of same sex couples to surrogacy. The majority of the respondents (53%) fear that the surrogacy may transform poor women into incubators for babies. This opinion is shared by the men, by the youngest and the oldest respondents and by the unmarried persons.

P.3.c.067 One year study: efficacy of haloperidol versus risperidone in the treatment of schizoaffective disorder

2010 ◽  
Vol 20 ◽  
pp. S496-S497
Author(s):  
D. Siladji Mladenovic ◽  
S. Drezgic Vukic ◽  
B. Golubovic ◽  
A. Ivezic
Keyword(s):  
Schizoaffective Disorder ◽  
One Year

Socio-demographic influences on language structure and change: Not all learners are the same

2016 ◽  
Vol 39 ◽  
Author(s):  
Till Bergmann ◽  
Rick Dale ◽  
Gary Lupyan
Keyword(s):  
Adult Learners ◽  
Large Share ◽  
Demographic Differences ◽  
Language Structure

AbstractThe Now-or-Never bottleneck has important consequence for understanding why languages have the structures they do. However, not addressed by C&C is that the bottleneck may interact with who is doing the learning: While some languages are mostly learned by infants, others have a large share of adult learners. We argue that such socio-demographic differences extend and qualify C&C's thesis.

Sign in / Sign up

Export Citation Format

Share Document